YU134287A - Process for obtaining pharmaceutic compound for stimmulating granulocite - Google Patents

Process for obtaining pharmaceutic compound for stimmulating granulocite

Info

Publication number
YU134287A
YU134287A YU01342/87A YU134287A YU134287A YU 134287 A YU134287 A YU 134287A YU 01342/87 A YU01342/87 A YU 01342/87A YU 134287 A YU134287 A YU 134287A YU 134287 A YU134287 A YU 134287A
Authority
YU
Yugoslavia
Prior art keywords
stimmulating
granulocite
pharmaceutic
obtaining
compound
Prior art date
Application number
YU01342/87A
Other versions
YU47543B (en
Inventor
M Machida
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of YU134287A publication Critical patent/YU134287A/en
Publication of YU47543B publication Critical patent/YU47543B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
YU134287A 1986-07-18 1987-07-17 PROCEDURE FOR OBTAINING PHARMACEUTICAL PREPARATION FOR GRANULLocyte Stimulation YU47543B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP16948686 1986-07-18
JP16948986 1986-07-18
JP16948886 1986-07-18
JP16948786 1986-07-18

Publications (2)

Publication Number Publication Date
YU134287A true YU134287A (en) 1989-06-30
YU47543B YU47543B (en) 1995-10-03

Family

ID=27474266

Family Applications (1)

Application Number Title Priority Date Filing Date
YU134287A YU47543B (en) 1986-07-18 1987-07-17 PROCEDURE FOR OBTAINING PHARMACEUTICAL PREPARATION FOR GRANULLocyte Stimulation

Country Status (24)

Country Link
KR (1) KR930004597B1 (en)
CN (1) CN1033738C (en)
AT (1) AT402259B (en)
AU (1) AU611856B2 (en)
BE (1) BE1000253A3 (en)
CA (1) CA1297007C (en)
CH (1) CH671157A5 (en)
DE (1) DE3723781C2 (en)
DK (1) DK171308B1 (en)
ES (1) ES2010226A6 (en)
FR (1) FR2601591B1 (en)
GB (1) GB2193631B (en)
GR (1) GR871067B (en)
HK (1) HK64893A (en)
HU (1) HU198627B (en)
IE (1) IE60290B1 (en)
IL (1) IL83220A (en)
IT (1) IT1218927B (en)
NL (1) NL192917C (en)
NO (1) NO171828C (en)
PT (1) PT85343B (en)
SE (1) SE503312C2 (en)
SG (1) SG64393G (en)
YU (1) YU47543B (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
NZ228285A (en) * 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US6132763A (en) * 1988-10-20 2000-10-17 Polymasc Pharmaceuticals Plc Liposomes
US5349052A (en) * 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
GB8824591D0 (en) * 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP3249147B2 (en) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
EP0459516A1 (en) * 1990-06-01 1991-12-04 Kirin-Amgen, Inc. Oral dosage form of biologically active proteins
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2693907B1 (en) * 1992-07-23 1994-09-02 Rhone Poulenc Rorer Sa A method of administering granulocyte colony stimulating factor solutions.
EP0582932A1 (en) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutic system for the parenteral administration of hematopoietic growth factors
DE4242919A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Process for the preparation of storage-stable aqueous pharmaceutical preparations of G-CSF
DE4242863A1 (en) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
TW434021B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable TPO-containing compositions
TW434020B (en) * 1995-03-15 2001-05-16 Kirin Brewery Methods for preventing adsorption of thrombopoietin (TPO), and stable top-containing compositions
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
JP3895109B2 (en) * 1998-03-06 2007-03-22 中外製薬株式会社 Protein-free formulation
US6979442B1 (en) * 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
TWI245645B (en) * 1999-09-08 2005-12-21 Chugai Pharmaceutical Co Ltd Protein solution formulations and stabilization methods thereof
TR200401573T4 (en) 2000-02-29 2004-08-23 Pfizer Products Inc. Stabilized granulocyte colony stimulating factor
WO2001064241A1 (en) * 2000-02-29 2001-09-07 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530839A (en) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション Albumin fusion protein
AU2001282607B2 (en) * 2000-09-01 2006-08-17 Chugai Seiyaku Kabushiki Kaisha Solution preparations stabilized over long time
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
EP1541585B1 (en) 2002-08-27 2013-01-30 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
AU2004216298B2 (en) 2003-02-28 2009-04-23 Chugai Seiyaku Kabushiki Kaisha Stabilized protein-containing formulations
DE202006020194U1 (en) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF liquid formulation
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
EP2396023A2 (en) 2009-02-11 2011-12-21 Yeda Research and Development Co. Ltd. Short beta-defensin-derived peptides
RU2519031C1 (en) 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Liquid formulations for long-acting conjugate of g-csf
EP2399572A1 (en) 2010-06-22 2011-12-28 Sandoz AG Long-term storage of non-glycosylated recombinant human G-CSF
KR20210089270A (en) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 Compositions and methods for treating cancer
BR112018016924A2 (en) 2016-02-23 2019-01-02 Biokine Therapeutics Ltd treatment regimen selection method for individual who has acute myeloid leukemia (LMA), acute response myeloid leukemia (LMA) treatment maximization method, lma treatment method, cxcr4 antagonist, and chemotherapeutic agent in the treatment of lma
WO2018138267A1 (en) 2017-01-27 2018-08-02 Cinfa Biotech S.L. Method for determining the efficacy of a g-csf containing composition
EP3797752A4 (en) * 2018-05-21 2022-03-02 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass vial

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2652636A1 (en) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Stabilising protein during separation, purification and storage - by adding amphiphilic cpds., esp. lipid(s), ionic and or nonionic detergents
SE451844B (en) * 1978-03-20 1987-11-02 Morinaga Milk Industry Co Ltd GLYCOPROTEIN, PROCEDURE FOR PREPARING THEREOF AND THERAPEUTIC AGENTS INCLUDING THE GLYCOPROTEIN
US4609546A (en) * 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
JPS60228422A (en) * 1984-04-26 1985-11-13 Suntory Ltd Stabilized preparation of physiologically active substance
JPS61227526A (en) * 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd Novel csf and method of collecting same
JPS6191131A (en) * 1984-10-09 1986-05-09 Chugai Pharmaceut Co Ltd Method and composition for preventing adsorption of pharmaceutical
DE3686794T2 (en) * 1985-02-05 1993-03-04 Cetus Oncology Corp CLEANING THE NATURAL COLONY-STIMULATING FACTOR-1.
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPH0618778B2 (en) * 1985-10-04 1994-03-16 中外製薬株式会社 Leukopenia treatment

Also Published As

Publication number Publication date
BE1000253A3 (en) 1988-09-27
SE8702907L (en) 1988-01-19
IE60290B1 (en) 1994-06-29
IL83220A (en) 1993-01-31
DK171308B1 (en) 1996-09-02
DK368387D0 (en) 1987-07-15
ATA177587A (en) 1996-08-15
PT85343A (en) 1987-08-01
FR2601591B1 (en) 1991-04-26
SG64393G (en) 1993-08-06
AU7566587A (en) 1988-01-21
GB2193631B (en) 1990-11-21
NL192917C (en) 1998-05-07
ES2010226A6 (en) 1989-11-01
HK64893A (en) 1993-07-16
NO171828B (en) 1993-02-01
AT402259B (en) 1997-03-25
SE8702907D0 (en) 1987-07-17
DE3723781A1 (en) 1988-01-21
IE871933L (en) 1988-01-18
YU47543B (en) 1995-10-03
DE3723781C2 (en) 1999-09-02
PT85343B (en) 1990-04-30
IL83220A0 (en) 1987-12-31
GB2193631A (en) 1988-02-17
CN1033738C (en) 1997-01-08
DK368387A (en) 1988-01-19
FR2601591A1 (en) 1988-01-22
AU611856B2 (en) 1991-06-27
NO872966D0 (en) 1987-07-16
CN87104963A (en) 1988-02-24
IT8767594A0 (en) 1987-07-10
HUT44941A (en) 1988-05-30
NL192917B (en) 1998-01-05
IT1218927B (en) 1990-04-24
NO872966L (en) 1988-01-19
KR880001297A (en) 1988-04-22
CA1297007C (en) 1992-03-10
KR930004597B1 (en) 1993-06-01
NL8701640A (en) 1988-02-16
GB8716904D0 (en) 1987-08-26
SE503312C2 (en) 1996-05-13
NO171828C (en) 1993-05-12
GR871067B (en) 1987-11-19
CH671157A5 (en) 1989-08-15
HU198627B (en) 1989-11-28

Similar Documents

Publication Publication Date Title
YU134287A (en) Process for obtaining pharmaceutic compound for stimmulating granulocite
YU92788A (en) Process for obtaining pharmaceutic compound of cephuroxime axetyl
PT85174A (en) Process for preparing azabiciclic compounds
YU154986A (en) Process for obtaining bis-phosphitic compounds
YU44797B (en) Process for producing substituted pyridinsulphonamde compound
YU40688A (en) Process for obtaining piperazinyl-heterocyclic compounds
YU223987A (en) Process for obtaining spiro-substituted glutaramidic compounds
YU44294B (en) Process for obtaining new antihypertenzic compounds
YU173088A (en) Process for obtaining trans-mucosalic compounds
YU73987A (en) Process for obtaining hynoline derivatives
YU131088A (en) Process for obtaining 1-terciaric-alkyl-substituted naphtiridine- and hynolin-carboxylic intermediers
PT82062A (en) Process for preparing pyridinylimidazolidinone compounds
YU36388A (en) Process for obtaining antihipercholesterolic tetrazolic compounds
YU202889A (en) Process for obtaining heterocyclical compounds
GR861004B (en) Process for preparing fluorized benzyltriazol compounds
YU224587A (en) Process for stabilizingwater solution ravitidine
YU30388A (en) Process for obtaining arylpiperazinylalkylenephenyl-heterocyclic compounds
YU105387A (en) Process for obtaining some substituted-3-amino-2-benzoilcyclohex-2-nones
YU74685A (en) Process for obtaining topical pharmaceutic compound
HUT46009A (en) Process for producing 7-bromo-beta-carboline compounds
YU134388A (en) Process for obtaining transdermal lamelled pharmaceutic compound with extended effect
YU118187A (en) Process for obtaining mercaptoacylproline
HUT40795A (en) Process for preparing fluoro-alkane compounds
YU26685A (en) Process for obtaining pharmaceutic substance with depot-effect
PT84279A (en) Process for preparing 2-aminoacyloxymethyl-2-penem compounds